Home » Posts tagged 'prostate cancer'
Tag Archives: prostate cancer
Prostate-specific membrane antigen PET-MRI validation of MR textural analysis for detection of transition zone prostate cancer? – Feedback (FDBK)
Bates A, et al. Eur Radiol. 2017.
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR.
METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis. Texture features of the TZ were compared to PSMA expression on the corresponding PET images. The Benjamini-Hochberg correction controlled the false discovery rate at <5%.
RESULTS: Eighty-eight T2-weighted images in 18 patients demonstrated abnormal PSMA expression within the TZ on PET-MR. 123 images were PSMA negative. Based on the corrected p-value of 0.005, significant differences between PSMA positive and negative slices were found for 16 texture parameters: Standard deviation and mean of positive pixels for all spatial filters (p = <0.0001 for both at all spatial scaling factor (SSF) values) and mean intensity following filtration for SSF 3-6 mm (p = 0.0002-0.0018).
CONCLUSION: Abnormal expression of PSMA within the TZ is associated with altered texture on T2-weighted MR, providing validation of MRTA for the detection of TZ prostate cancer.
KEY POINTS: Prostate transition zone (TZ) MR texture analysis may assist in prostate cancer detection. • Abnormal transition zone PSMA expression correlates with altered texture on T2-weighted MR. • TZ with abnormal PSMA expression demonstrates significantly reduced MI, SD and MPP.
Copyright © 2017 The Royal College of Radiologists. All rights reserved.
Original article link here
Feedback PLC director Dr Balaji Ganeshan joins Justin Waite on the ADVFN podcast to discuss the latest developments with TexRAD in regard to joint ventures for prognosis and treatment for Lung Cancer, Kidney Stones and Prostate Cancer. He also explains the background of the company, how doctors use and access the software. The interview is just over 21 minutes in. Click here to listen.
From the Spanish medical website Tu hospital investiga para ti
The Spin-Off of the IIS La Fe, Quibim has established a strategic alliance with UK company Feedback Plc to develop Prostate Checker, a tool that will improve the diagnosis of prostate cancer.
Feedback Plc acquired last year TexRAD company dedicated to the analysis of tumor from medical images textures, and began negotiating with Quibim in June this year in order to integrate the analysis modules of cell broadcasting and angiogenesis tumor that develops the Valencian company.
The information provided by Quibim be integrated with the texture analysis of Feedback in a single tool, under the name of Prostate Checker. These imaging biomarkers can be obtained from the advanced processing of MRI and is now considered the revolution He is undergoing radiology to become an indispensable tool in the framework of Medicine Precision “.
Quibim is an innovative company, founded in 2012, especially dedicated to medical image processing and extraction of imaging biomarkers in the radiological workflow.
More information Prostatechecker
More information Quibim
– See more at: http://www.shareprophets.com/views/15537/feedback-and-the-big-spanish-connection#sthash.d1mviXV7.dpuf
By Michaela Morris in Health, Lifestyle, Daily Journal
Dick Guyton is glad he made the decision to continue with prostate cancer screening.
After being diagnosed with early stage disease in May 2013, he took his time and gathered all the options for treatment before deciding on a course of action with his medical team.
Link here for full story